What is a biomarker in drug development, and how can it guide dose selection and patient stratification?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Multiple Choice

What is a biomarker in drug development, and how can it guide dose selection and patient stratification?

Biomarkers are measurable indicators of biology that reflect how a drug affects its target and the downstream biology. In drug development, they are used to connect drug exposure to a biological effect, which in turn helps pick the right dose and the right patients. For dose selection, biomarkers show how much target engagement or pathway modulation occurs at different doses, helping identify the dose that achieves sufficient biological effect while keeping safety within limits. They provide a real-time readout of whether the drug is hitting its intended target and producing the expected downstream changes, which helps avoid under- or over-dosing. For patient stratification, biomarkers enable enrichment by identifying subgroups more likely to respond or less likely to experience harm. This can involve genetic, proteomic, imaging, or other measurable parameters that predict efficacy or risk, guiding inclusion criteria and personalized treatment approaches. Examples include imaging readouts of receptor occupancy, phosphorylated signaling proteins as pharmacodynamic readouts, or circulating protein markers that change with target engagement. Tracking these markers throughout development helps optimize dose and select the patients most likely to benefit. The other options don’t fit because they’re not indicators of biological processes or drug effects: a marketing label doesn’t reflect biology; a genetic variant with no clinical relevance isn’t informative for dosing or response; a solvent used in manufacturing has no biological meaning for drug activity or patient response.

Biomarkers are measurable indicators of biology that reflect how a drug affects its target and the downstream biology. In drug development, they are used to connect drug exposure to a biological effect, which in turn helps pick the right dose and the right patients.

For dose selection, biomarkers show how much target engagement or pathway modulation occurs at different doses, helping identify the dose that achieves sufficient biological effect while keeping safety within limits. They provide a real-time readout of whether the drug is hitting its intended target and producing the expected downstream changes, which helps avoid under- or over-dosing.

For patient stratification, biomarkers enable enrichment by identifying subgroups more likely to respond or less likely to experience harm. This can involve genetic, proteomic, imaging, or other measurable parameters that predict efficacy or risk, guiding inclusion criteria and personalized treatment approaches.

Examples include imaging readouts of receptor occupancy, phosphorylated signaling proteins as pharmacodynamic readouts, or circulating protein markers that change with target engagement. Tracking these markers throughout development helps optimize dose and select the patients most likely to benefit.

The other options don’t fit because they’re not indicators of biological processes or drug effects: a marketing label doesn’t reflect biology; a genetic variant with no clinical relevance isn’t informative for dosing or response; a solvent used in manufacturing has no biological meaning for drug activity or patient response.

More practice questions